Oncologists’ Treatment Rationale and Wish-List in IO

The latest release from our annual corporate leadership reveals multiple factors supporting the use of an IO approach having similar impact on treatment decisions. Factors most driving oncologist usage were efficacy and quality of life benefits offered by IO treatments followed by label safety and availability of biomarkers. With little geographical difference, US oncologists stressed more importance on the rate of disease progression compared to their EU based colleagues.

Click to Enlarge

Oncologists also shared that information about efficacy is their most desired area for improvement by pharma. Information on side effects and use in expanded indications for earlier disease were preferred more by EU based physicians whilst US colleagues stressed greater importance on quality of life and real-world evidence.

About the study

The 2020 Corporate Leadership Study was conducted with 100 oncologists across US and EU using ONCpulseTM  agile research solution. ONCpulseTM answers today’s business questions tomorrow through global access to 130,000+ experts and treaters in oncology, hematology and complex rare diseases.

The objectives of the study were:

  • Defining what ‘corporate leadership’ means to the oncology community
  • Revealing the leaders (in oncology and IO) and an evaluation of their performance by oncologists
  • Assessing current barriers and drivers to IO treatment choice and identifying oncologist views on areas for needed improvement by pharma.

Clients like you invest in MDoutlook as their partner of choice thanks to the positive accolade garnered from praise across the industry.

Want a report copy?

Sign up by clicking here.

If you would like a personalized leadership briefing and map out your teams future success, let’s take the next step to arrange a meeting using the Calendly link or by contacting us at [email protected] or via +1 404 496 4136.

Mastering Virtual Conference Data Presentation Impact

With ASCO announcing their inaugural virtual program last week and ahead of other major oncology and hematology conferences (such as EHA) moving online, client appetite for planning their activities have not abated in hiring us to measure impact of their data announcement activity in the current “new norm”.

Have you planned measurement of your upcoming virtual conference activity?

Irrespective of the meeting format, measuring data announcement impact is more important than ever. With the deluge of scientific data presentations planned, clients are eager to assess the effectiveness of the virtual conference format and assess the impact of their activities in breaking through the competitive noise. Through access to the largest validated global online community of 130,000+ ThoughtLeaders and treaters (in oncology, hematology and complex rare diseases) are we able to get to your core targets to evaluate whether announcements change oncologists’ behavior and estimate how a data presentation influences their future treatment decisions and clinical practice.

Be the first to know!

Clients often find themselves in a situation where they need to quickly understand the implications of their own and competitors’ conference data announcements. For one of our clients we recruited 500 oncologists across 30 countries within a week of the conference via our agile ONCpulseTM research service. Timely access to the results allowed our client to confidently react quickly to our insights! Often, we are the first to offer in-depth results after a congress.

Client feedback

“Rapid results allowed us to adapt our commercialization plans for the following year and assess success of our own data announcements. This is very useful for us in light of next year’s planning”.

Brand Director Oncology, Major Pharmaceutical Company

Tracking your impact post conference matters

Whilst measuring conference impact is important, tracking follow-up activity from a conference is of even greater importance and should not be overlooked when assessing the influence and reach of your messages. In the current “new-norm”, these channels for communication will be less affected!

Conference data announcements speak volumes and the virtual format will similarly be as impactful. However, the importance of measuring follow-up and impact from messaging activity post-conference is neatly highlighted from a client survey of 147 US oncologists in showing little difference with attention captured at conferences when compared to post-conferences.

Click to Enlarge

About half (n=75) of US oncologists who did not attend the conference rated their awareness of the news as relatively high. Nearly two-thirds of academic non-attendees rated their awareness of conference results as high or very high and by comparison, still almost half of US community oncologists rated their level of awareness on a similar basis. We must not forget that non-attendees choice for staying up-to-date of information post conference will in most cases be via digital communication channels and least affected by the current situation.

Conference research specialists

Are you currently facing the challenge of measuring the impact of your scientific data presentation in the “new-norm”? For clients like you we make this process easy. With 10+ years’ experience and more than 140 projects under our belt, take the next easy step to meet using the calendar link or contact us at [email protected] or call +1.404.496.4136.

Choose MDoutlook to measure the success of your scientific data presentation.